Product Information
QUDEXY XR 200 MG CAPSULE is a brand product labeled by Upsher-Smith Laboratories LLC, priced at $32.8758 per EA under NDC 00245107330. Its NADAC has been published 175 times since Sep 18, 2019.
FDA first approved this application on Mar 11, 2014. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Upsher-Smith Laboratories LLCNDC
00245107330
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
4/23/2025
Active Ingredients
TOPIRAMATEApproval Type
New Drug (NDA)
FDA Application
NDA205122FDA Approved
3/11/2014
TE Code
AB2
On Market Since
4/11/2014
Pharmacological Classes
Price Statistics
The NADAC for QUDEXY XR 200 MG CAPSULE has been published 175 times since Sep 18, 2019, and over the history we have for it it has risen 22.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $32.8758 per EA |
|---|---|
| All-time high | $32.8758 (Apr 15, 2026) |
| All-time low | $26.8832 (Sep 18, 2019) |
| 52-week high | $32.8758 |
| 52-week low | $32.8758 |
| Median price | $32.7310 |
| Average price | $30.9063 |
| Largest weekly change | +14.9% (Apr 17, 2024) |
| Weeks tracked | 175 |
| Tracking since | Sep 18, 2019 |
1W
N/A
1M
N/A
3M
N/A
6M
0.0%
1Y
0.0%
3Y
+15.4%
5Y
+15.4%
All
+22.3%
Last surveyed Apr 15, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 71% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Upsher-Smith Laboratories LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QUDEXY XR 200 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for QUDEXY XR 200 MG CAPSULE, manufactured by Upsher-Smith Laboratories LLC, is $32.8758 per EA (NDC 00245107330), effective Apr 15, 2026.
How has the price of QUDEXY XR 200 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for QUDEXY XR 200 MG CAPSULE has risen 22.3%. It has been tracked across 175 weekly CMS publications since Sep 18, 2019.
What are the highest and lowest recorded NADAC prices for QUDEXY XR 200 MG CAPSULE?
Since Sep 18, 2019, the NADAC for QUDEXY XR 200 MG CAPSULE has ranged from a low of $26.8832 (Sep 18, 2019) to a high of $32.8758 (Apr 15, 2026), with a median of $32.7310 per EA.
Are there cheaper alternatives to QUDEXY XR 200 MG CAPSULE?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOPIRAMATE ER 200 MG SPRINK CAP, is $9.5420 per EA — about 71% below QUDEXY XR 200 MG CAPSULE.
Who manufactures QUDEXY XR 200 MG CAPSULE?
QUDEXY XR 200 MG CAPSULE (NDC 00245107330) is labeled by Upsher-Smith Laboratories LLC, and CMS classifies it as a brand product.